Pharmacotherapy in Parkinson’s disease.
作者信息
Rose Olaf
出版信息
Med Monatsschr Pharm. 2016 Jul;39(7):286-92.
PMID:29953181
Abstract
Pharmacotherapy in Parkinson’s disease is complex, with dopaminergic stimulation as its backbone. During the past decade only a few new drugs have been registered. However, progress has been made in clinical experience. Recent studies suggest better and longer efficacy of MAO-B inhibitors. Therapy of advanced stages of Parkinson’s disease remains a challenge as the therapeutic window narrows and motor complications prevail.
摘要
相似文献
1
Pharmacotherapy in Parkinson’s disease.
Med Monatsschr Pharm. 2016 Jul;39(7):286-92.
2
Current pharmacotherapeutic treatment options in Parkinson's disease.帕金森病当前的药物治疗选择。
Dis Mon. 2007 Apr;53(4):214-22. doi: 10.1016/j.disamonth.2007.05.002.
3
[The treatment of Parkinson's disease].[帕金森病的治疗]
Praxis (Bern 1994). 2013 Dec 11;102(25):1529-35. doi: 10.1024/1661-8157/a001505.
4
Drug therapy of Parkinson's disease. An overview.
Eur Neurol. 1992;32 Suppl 1:3-8. doi: 10.1159/000116864.
5
An MCASE approach to the search of a cure for Parkinson's Disease.一种寻找帕金森病治疗方法的MCase方法。
BMC Pharmacol. 2002 Apr 2;2:8. doi: 10.1186/1471-2210-2-8.
6
Treatment of levodopa-induced motor complications.左旋多巴诱发的运动并发症的治疗。
Mov Disord. 2008;23 Suppl 3:S599-612. doi: 10.1002/mds.22052.
7
Future therapies for Parkinson's disease.帕金森病的未来疗法。
Neurol Clin. 2004 Oct;22(3 Suppl):S149-66. doi: 10.1016/j.ncl.2004.05.005.
8
9
Parkinson's disease.帕金森病。
Clin Evid. 2002 Jun(7):1208-20.
10
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.莫洛贝胺（一种可逆性选择性单胺氧化酶A抑制剂）在帕金森病中的治疗潜力。
J Clin Psychopharmacol. 1995 Aug;15(4 Suppl 2):51S-59S. doi: 10.1097/00004714-199508001-00010.
Zotero 插件